Advertisement
News
Advertisement

Clinical Data sells off pharmacogenomics assets

Tue, 11/30/2010 - 5:33am
Mass High Tech: The Journal of New England Technology

Clinical Data Inc. is selling its pharmacogenomics and biomarker development business for $15.4 million to Omaha, Neb.-based Transgenomic Inc. The sale of the Newton firm’s Familion genetic tests and the biomarkers of the PGxPredict tests is the last step for Clinical Data in transforming to a pharmaceutical firm, according to a news release

The $15.4 million transaction includes $6 million in cash, a three-year promissory note for $8.5 million and a one-year promissory note for $932,000. Clinical Data will also collect milestone payments and royalty on development of pharmacogenomic diagnostic products. The company is also due a portion of Transgenomic’s accounts receivable – up to $1.8 million.

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading